OSCR
Oscar Health, Inc.
OSCR has the edge over RDNT overall, supported by stronger fundamentals and stronger modeled upside.
RDNT
RadNet, Inc.
RDNT has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RDNT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
RDNT's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RDNT PE Valuation
RDNT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RDNT on the outlook, with more favorable profitability expectations.
RDNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for RDNT, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RDNT on earnings quality, reporting a profit while its opponent remains loss making.
RDNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | — |
| Q3 2026 | -$0.28 | -$0.11 |
| Q2 2026 | -$0.26 | -$0.06 |
| Q1 2026 | -$0.17 | +$0.26 |
| Q4 2025 | -$0.25 | -725% |
| Q3 2025 | -$0.17 | -$0.17 |
| Q2 2025 | -$0.20 | -195% |
| Q1 2025 | -$0.43 | -216% |
| Q4 2024 | $0.04 | -20% |
RDNT is still losing money, but less than at its worst: $0.28 per share over the past year, against $0.43 at its worst in early 2025.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RDNT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RDNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $638.3M | +22% |
| Q2 2026 | $622.7M | +25% |
| Q1 2026 | $575.6M | +22% |
| Q4 2025 | $547.7M | +15% |
| Q3 2025 | $522.9M | +13% |
| Q2 2025 | $498.2M | +8.4% |
| Q1 2025 | $471.4M | +9.2% |
| Q4 2024 | $477.1M | +13% |
RDNT's revenue has grown year over year every quarter since late 2020: $638M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.7% | -0.5 points |
| Q2 2026 | 6.3% | +0.1 points |
| Q1 2026 | -4.2% | +1 points |
| Q4 2025 | 5.1% | -0.1 points |
| Q3 2025 | 5.2% | -2.1 points |
| Q2 2025 | 6.2% | -1.4 points |
| Q1 2025 | -5.1% | -7.7 points |
| Q4 2024 | 5.1% | -0.7 points |
RDNT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RDNT on cash flow, with more consistent year-over-year improvement.
RDNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +$42.7M |
| Q2 2026 | $37.8M | -44% |
| Q1 2026 | $9M | +$16.4M |
| Q4 2025 | $33.1M | +$33.5M |
| Q3 2025 | -$7.6M | -147% |
| Q2 2025 | $67.4M | -2.8% |
| Q1 2025 | -$7.4M | +$33M |
| Q4 2024 | -$377K | -101% |
RDNT generated $115M in free cash flow over the past year, up 121% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RDNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +443K shares |
| 1 year | +2.3% | +1.8M shares |
| 3 years | +15% | +10.4M shares |
| 5 years | +47% | +25.4M shares |
| Available history | +57% | +28.9M shares |
RDNT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RDNT on leverage, with a lower net debt burden relative to earnings.
RDNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.1x | Healthy |
RDNT's net debt is about 2.3 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RDNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.3 | Neutral |
| Stochastic | 65.1 | Neutral |
RDNT's weekly RSI is 60 (neutral) and its Stochastic is 65 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RDNT PE vs Healthcare Sector
| Metric | RDNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDNT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
RDNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.0 | 5.6% above |
| 20 week MA | $71.2 | 6.8% above |
| 50 week MA | $66.8 | 14% above |
| 100 week MA | $65.1 | 17% above |
| 200 week MA | $54.2 | 40% above |
RDNT is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RDNT on returns for 2026, with the stronger performance.
RDNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.9 | $18.7 | -5.8% |
| 2021 | $18.7 | $30.4 | +62% |
| 2022 | $30.4 | $18.9 | -38% |
| 2023 | $18.9 | $34.8 | +84% |
| 2024 | $34.8 | $71.3 | +105% |
| 2025 | $71.3 | $73.2 | +2.6% |
| 2026 YTD | $73.2 | $76.0 | +4% |
RDNT has finished higher in four of the last six years, three of them by more than 50%. It's up 4% so far in 2026.